#leukemia

Moxetumomab pasudotox “offers an option for patients with relapsed or refractory hairy cell leukemia that avoids additional chemotherapy.”

Approval was based on improves progression-free survival in the MURANO trial.

“When your doctor says the No. 1 pediatric stem cell transplant hospital in the world is 90 minutes from your house, you don’t question it...

New tech enables deep dive into mysterious results, sets stage for future improvements.

The link between the older interferon treatment and these cancers may be related to the drug’s low hep C cure rate.

Aside from taking antiretrovirals, quitting smoking is the number one way people with HIV can lower their risk of illness and death.

Approval extended to people who are in remission but have minimal residual disease.

Researchers have been working to develop more targeted, less toxic treatments for childhood B-cell acute lymphoblastic leukemia (ALL).

Approval was based on trials enrolling newly diagnosed patients and those with resistant disease.

Patients whose cancer responds rapidly to nilotinib are more likely to maintain their remission.

Childhood cancers are often the result of DNA mutations that take place early in life, sometimes even before birth.

Cutting-edge approach creates customized therapy.

A new study in childhood leukemia illustrates challenges and power of cutting-edge genomic technologies’ huge data sets.

Much work remains to better understand the underlying biology of blood cancers in adolescents and young adults.

Venclexta combination therapy clears leukemia in blood and bone marrow, recent studies show.